Semin Liver Dis 2009; 29(1): 003-018
DOI: 10.1055/s-0029-1192052
© Thieme Medical Publishers

Liver Transplantation: The Current Situation

Rene Adam1 , 2 , 3 , Emir Hoti1 , 4
  • 1AP-HP Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France
  • 2Université Paris-Sud, Villejuif, France
  • 3Inserm, Unité, Villejuif, France
  • 4Liver Transplant Unit, Saint Vincent's University Hospital, Dublin, Ireland
Further Information

Publication History

Publication Date:
23 February 2009 (online)


Over the years, an improving liver transplant (LT) survival rate (1- and 5-year survival of 83% and 75%, respectively) has been instrumental in establishing transplant surgery as a durable therapy for all forms of end-stage liver disease and for some malignant conditions. The success of such treatment has resulted in a progressively increasing demand for liver transplantation. However, at the same time the availability of donor organs has diminished, resulting in the number of potential recipients for liver transplantation exceeding organ supply. Several strategies have been explored with the aim to increase access to liver transplantation, including: obtaining organs from non-heart-beating donors and live donors, and splitting and using livers from expanded donor criteria. This article discusses the utility of the mentioned techniques along with other strategies (e.g., Model for End-Sage Liver Disease [MELD] score), as well as the evolution of indications, contraindications, and postoperative care.


  • 1 European Liver Transplant Registry .Data analysis booklet. Paris 2007. Available at: Accessed August 2008
  • 2 United Network for Organ Sharing .Available at: Accessed August 2008
  • 3 Everhart J E, Beresford T P. Liver transplantation for alcoholic liver disease: a survey of transplantation programs in the United States.  Liver Transpl Surg. 1997;  3 220-226
  • 4 Perney P, Bismuth M, Siguard H et al.. Are preoperative patterns of alcohol consumption predictive of relapse after liver transplantation for alcoholic liver disease?.  Transpl Int. 2005;  18 1292-1297
  • 5 Miguet M, Monnet E, Vanlemmens C et al.. Predictive factors of alcohol relapse after orthotopic liver transplantation for alcoholic liver disease.  Gastroenterol Clin Biol. 2004;  28 845-851
  • 6 Tome S, Martinez-Rey C, Gonzales-Quintela A et al.. Influence of superimposed alcoholic hepatitis on the outcome of liver transplantation for end-stage liver disease.  J Hepatol. 2002;  36 793-798
  • 7 Neuberger J, Schulz K H, Day C et al.. Transplantation for alcoholic liver disease.  J Hepatol. 2002;  36 130-137
  • 8 Pageaux G P, Bismuth M, Penny P et al.. Alcohol relapse after liver transplantation for alcoholic liver disease: does it matter?.  J Hepatol. 2003;  38 629-634
  • 9 Johnson M W, Washburn W K, Freeman R B et al.. Hepatitis C viral infection in liver transplantation.  Arch Surg. 1996;  131 284-291
  • 10 Rosen H R, O'Reilly P M, Shackleton C R et al.. Graft loss following liver transplantation in patients with chronic hepatitis C.  Transplantation. 1996;  62 1773-1776
  • 11 Russo M W, Galanko J, Beavers K et al.. Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States.  Liver Transpl. 2004;  10 340-346
  • 12 Mazzaferro V, Regalia E, Doci R et al.. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.  N Engl J Med. 1996;  334 693-699
  • 13 Yao F Y, Ferrell L, Bass N M et al.. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.  Hepatology. 2001;  33 1394-1403
  • 14 Edwards E, Harper A. Does MELD work for relisted candidates?.  Liver Transpl. 2004;  10 S10-S16
  • 15 Castells L, Escartin A, Bilbao I et al.. Liver transplant in HIV-HCV coinfected patients: a case control study.  Transplantation. 2007;  83 354-358
  • 16 Roland M E, Stock P G. Liver transplantation in HIV-infected recipients.  Semin Liver Dis. 2006;  26 273-284
  • 17 Sudan D, De Roover A, Chinnakotla S et al.. Radiochemotherapy and transplantation allows long term survival for non resectable hilar cholangiocarcinoma.  Am J Transplant. 2002;  2 774-779
  • 18 Shaw B W, Iwatsuki S, Bron K, Starzl T E. Portal vein grafts in hepatic transplantation.  Surg Gynecol Obstet. 1985;  161 66-68
  • 19 O'Grady J G, Alexander G J, Hayllar K M, Williams R. Early indicators of prognosis in fulminant hepatic failure.  Gastroenterology. 1989;  97 439-445
  • 20 Bernuau J, Goudeau A, Poynard T et al.. Multivariate analysis of prognostic factors in fulminant hepatitis B.  Hepatology. 1986;  6 648-651
  • 21 Grazi G L, Cescon M, Ravaioli M et al.. A revised consideration on the use of very aged donors for liver transplantation.  Am J Transplant. 2001;  1 61-68
  • 22 Verran D, Kusyk T, Painter D et al.. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation.  Liver Transpl. 2003;  9 500-505
  • 23 Russo M W, Galanko J A, Zacks S L et al.. Impact of donor age and year of transplantation on graft survival in liver transplant recipients with chronic hepatitis C.  Am J Transplant. 2004;  4 1133-1138
  • 24 Rayhill S C, Wu Y M, Katz D A et al.. Older donor livers show early histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C.  Transplantation. 2007;  84 331-339
  • 25 Strasberg S M, Howard T K, Molmenti E P et al.. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation.  Hepatology. 1994;  20 829-838
  • 26 Pedotti P, Cardillo M, Rigotti P et al.. A comparative prospective study of two available solutions for kidney and liver transplantation.  Transplantation. 2004;  77 1540-1545
  • 27 Adam R, Caillez V, Majno P et al.. Normalised intrinsic mortality risk in liver transplantation: European Liver Transplant Registry study.  Lancet. 2000;  356 621-627
  • 28 Briceno J, Marchal T, Padillo J et al.. Influence of marginal donors on liver preservation injury.  Transplantation. 2002;  74 522-526
  • 29 Piratvisuth T, Tredger J M, Hayllar K A, Williams R. Contribution of true cold and rewarming ischemia times to factors determining outcome after orthotopic liver transplantation.  Liver Transpl Surg. 1995;  1 296-301
  • 30 Clavien P A, Harvey P R, Strasberg S M. Preservation and reperfusion injuries in liver grafts. An overview and synthesis of current studies.  Transplantation. 1992;  53 957-978
  • 31 Dunne J B, Piratvisuth T, Williams R, Tredger J M. Treatment of experimental ischemia/reperfusion injury with S-adenyosylmethionine: evidence that donor pretreatment complements other regimens.  Transplantation. 1997;  63 500-506
  • 32 Nery J R, Nery-Avila C, Reddy K R et al.. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine.  Transplantation. 2003;  75 1179-1186
  • 33 Gane E J, Angus P W, Strasser S et al.. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation.  Gastroenterology. 2007;  132 931-937
  • 34 Velidedeoglu E, Desai N M, Campos L et al.. The outcome of liver grafts procured from hepatitis C donors.  Transplantation. 2002;  73 582-587
  • 35 Marroquin C E, Marino G, Kuo P C et al.. Transplantation of hepatitis C-positive livers in hepatitis C-negative patients is equivalent to transplanting hepatitis C-negative livers.  Liver Transpl. 2001;  7 762-768
  • 36 Khapra A P, Agarwal K, Fiel M I et al.. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV allografts.  Liver Transpl. 2006;  12 1496-1503
  • 37 Pomfret E A, Pomposelli J J, Lewis W D et al.. Live donor adult liver transplantation using right lobe grafts: donor evaluation and surgical outcome.  Arch Surg. 2001;  136 425-433
  • 38 Grewal H P, Shokouh-Amiri M H, Vera S, Stratta R, Bagous W, Gaber A O. Surgical technique for right lobe adult living donor living transplantation without venovenous bypass or portocaval shunting and with duct-to-duct biliary reconstruction.  Ann Surg. 2001;  233 502-508
  • 39 Trotter J F, Adam R, Lo C M, Kenison J. Documented deaths of hepatic lobe donors for living donor liver transplantation.  Liver Transpl. 2006;  12 1485-1488
  • 40 Renz J F, Roberts J P. Long-term complications of living donor liver transplantation.  Liver Transpl. 2000;  6 S73-S76
  • 41 Liver Donation. New York State Committee on Quality Improvement in Living Liver Donation. Available at: Accessed August 2008
  • 42 Berg C L, Gillespie B W, Merion R M A2ALL Study Group et al. Improvement in survival associated with adult-to-adult living donor transplantation.  Gastroenterology. 2007;  133 1806-1813
  • 43 Humar A, Ramcharan T, Sielaff T D et al.. Split liver transplantation for two adult recipients: an initial experience.  Am J Transplant. 2001;  1 366-372
  • 44 Andorno E, Genzone A, Morelli N et al.. One liver for two adults: in situ split liver transplantation for two adult recipients.  Transplant Proc. 2001;  33 1420-1422
  • 45 Azoulay D, Castaing D, Adam R et al.. Split-liver transplantation for two adult recipients: feasibility and long-term outcomes.  Ann Surg. 2001;  233 565-574
  • 46 Giacomoni A, Lauterio A, Donadon M et al.. Should we still offer split-liver transplantation for two adult recipients? A retrospective study of our experience.  Liver Transpl. 2008;  14 999-1006
  • 47 Berg C L, Gillespie B W, Merion R M et al.. Improvement in survival associated with adult-to-adult living donor liver transplantation.  Gastroenterology. 2007;  133 1806-1813
  • 48 Abt P, Crawford M, Desai N, Markmann J, Olthoff K, Shaked A. Liver transplantation from controlled non-heart-beating donors: an increased incidence of biliary complications.  Transplantation. 2003;  75 1659-1663
  • 49 Foley D P, Fernandez L A, Laverson G et al.. Donation after cardiac death: the University of Wisconsin experience with liver transplantation.  Ann Surg. 2005;  242 724-731
  • 50 Axelrod D A, Schnitzler M, Salavalaggio P R, Swindle J, Abecassis M M. The economic impact of the utilization of liver allografts with high donor risk index.  Am J Transplant. 2007;  7 990-997
  • 51 Feng S, Goodrich N P, Bragg-Gresham J L et al.. Characteristics associated with liver graft failure: The concept of a donor risk index.  Am J Transplant. 2006;  6 783-790
  • 52 Schaubel D E, Sima C S, Goodrich N P et al.. Survival benefit of transplantation by MELD and donor risk index.  Am J Transplant. 2006;  6 95
  • 53 Cameron A M, Ghobrial R M, Yersiz H et al.. Optimal utilization of donor grafts with extended criteria: a single-center experience in over 1000 liver transplants.  Ann Surg. 2006;  243 748-753
  • 54 Muiesan P, Girlanda R, Jassem W et al.. Single-center experience with liver transplantation from controlled non-heartbeating donors: a variable source of grafts.  Ann Surg. 2005;  242 732-738
  • 55 Fujita S, Misuno S, Fujikawa T et al.. Liver transplantation from donation after cardiac death: a single center experience.  Transplantation. 2007;  84 46-49
  • 56 Abt P L, Desai N M, Crawford M D et al.. Survival following transplantation from non-heart-beating donors.  Ann Surg. 2004;  239 87-92
  • 57 Merion R M, Pelletier S J, Goodrich N et al.. Donation after cardiac death as a strategy to increase deceased donor liver availability.  Ann Surg. 2006;  244 555-562
  • 58 Roberts J P, Hulbert-Shearon T E, Merion R M, Wolfe R A, Port F K. Influence of graft type on outcomes after pediatric liver transplantation.  Am J Transplant. 2004;  4 373-377
  • 59 Sindhi R, Rosendale R, Mundy D et al.. Impact of segmental grafts on pediatric liver transplantation—a review of the United Network for Organ Sharing Scientific Registry data (1990–1996).  J Pediatr Surg. 1999;  34 107-111
  • 60 Otte J B, de Ville de Goyet J, Reding R et al.. Living related donor liver transplantation in children: the Brussels experience.  Transplant Proc. 1996;  28 2378-2379
  • 61 Boillot O, Belghiti J, Azoulay D, Gugenheim J, Soubrane O, Cherqui D. Initial French experience in adult-to-adult living donor liver transplantation.  Transplant Proc. 2003;  35 962-963
  • 62 Foster R, Zimmerman M, Trotter J F. Expanding donor options: marginal, living and split liver donors.  Clin Liver Dis. 2007;  11 417-429
  • 63 Olthoff K M, Merion R M, Ghobrial R M et al.. Outcomes of 385 adult-to-adult living donor liver transplant recipients: a report from the A2All Consortium.  Ann Surg. 2005;  242 314-323
  • 64 Patel S, Orloff K M, Tsoulfas G et al.. Living donor liver transplantation in the United States: identifying donors at risk for perioperative complications.  Am J Transplant. 2007;  7 2344-2349
  • 65 Garcia Retortillo M, Forns X, Llovet J M et al.. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation.  Hepatology. 2004;  40 699-707
  • 66 Shiffman M L, Stravitz R T, Contos M L et al.. Histologic recurrence of chronic hepatitis C virus in patients after living donor compared to cadaveric liver transplantation.  Liver Transpl. 2004;  10 1248-1255
  • 67 Terrault N A, Shiffman M L, Lok A S et al.. Outcomes of hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation.  Liver Transpl. 2007;  13 122-129
  • 68 Schmeding M, Neumann U P, Puhl G, Bahra M, Neuhaus R, Neuhaus P. Hepatitis C recurrence and fibrosis progression are not increased after living donor liver transplantation: a single-center study of 289 patients.  Liver Transpl. 2007;  13 687-692
  • 69 Sarasin F P, Majno P E, Llovet J M et al.. Living donor liver transplantation for early hepatocarcinoma: a life expectancy and cost effectiveness perspective.  Hepatology. 2001;  33 1073-1079
  • 70 Todo S, Furukawa H. Japanese Study Group on Organ Transplantation . Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan.  Ann Surg. 2004;  240 451-459
  • 71 D'Alessandro A M, Knechtle S J, Chin L T et al.. Liver transplantation in pediatric patients: twenty years of experience at the University of Wisconsin.  Pediatr Transplant. 2007;  11 661-670
  • 72 Washburn K, Halff G, Mieles L et al.. Split-liver transplantation: results of statewide usage of the right trisegmental graft.  Am J Transplant. 2005;  5 1652-1659
  • 73 Yersiz H, Renz J F, Farmer D G et al.. One hundred in situ split-liver transplantations: a single-center experience.  Ann Surg. 2003;  238 496-505
  • 74 Wilms C, Walter J, Kaptein M et al.. Long-term outcome of split liver transplantation using right extended grafts in adulthood: a matched paired analysis.  Ann Surg. 2006;  244 865-872
  • 75 Cardillo M, De Fazio N, Pedotti P et al.. Split and whole liver transplantation outcomes: a comparative cohort study.  Liver Transpl. 2006;  12 402-410
  • 76 Helderman J H, Bennet W M, Cibrik D M et al.. Immunosuppression practice and trends.  Am J Transplant. 2003;  3 41-52
  • 77 Eason J D, Nair S, Cohen A J et al.. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy.  Transplantation. 2003;  75 1396-1399
  • 78 Heffron T G, Smallwood G A, Pillen T et al.. Liver transplant induction trial of daclizumab to spare calcineurin inhibition.  Transplant Proc. 2002;  34 1514-1515
  • 79 Pageaux G P, Calmus Y, Boillot O French CHI-F-01 Study Group et al. Steroid withdrawal at day 14 after liver transplantation: a double-blind, placebo-controlled study.  Liver Transpl. 2004;  10 1454-1460
  • 80 Ringe B, Braun F, Schutz E et al.. A novel management strategy of steroid free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil.  Transplantation. 2001;  71 508-515
  • 81 Haddad E M, McAlister V C, Renouf E, Malthaner R, Kjaer M S, Gluud L L. Cyclosporin versus tacrolimus for liver transplanted patients.  Cochrane Database Syst Rev. 2006;  4 CD005161
  • 82 McAlister V C, Haddad E M, Renouf E, Malthaner R, Kjaer M S, Gluud L L. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis.  Am J Transplant. 2006;  6 1578-1585
  • 83 Wiesner R, Rabkin J, Klintmalm G et al.. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients.  Liver Transpl. 2001;  7 442-450
  • 84 Zaghla H, Selby R R, Chan L S et al.. A comparison of sirolimus vs. calcineurin inhibitor-based immunosuppressive therapies in liver transplantation.  Aliment Pharmacol Ther. 2006;  23 513-520
  • 85 Levy G, Schmidli H, Punch J et al.. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results.  Liver Transpl. 2006;  12 1640-1648
  • 86 Trotter J F. Sirolimus in liver transplantation.  Transplant Proc. 2003;  35 193S-200S
  • 87 Karam V H, Gasquet I, Delvart V et al.. Quality of life in adult survivors beyond 10 years after liver, kidney, and heart transplantation.  Transplantation. 2003;  76 1699-1704
  • 88 Tome S, Wells J T, Said A, Lucey M R. Quality of life after liver transplantation. A systematic review.  J Hepatol. 2008;  48 567-577
  • 89 Johnston S D, Morris J K, Cramb R et al.. Cardiovascular morbidity and mortality after orthotopic liver transplantation.  Transplantation. 2002;  73 901-906
  • 90 Ojo A O, Held P J, Port F K et al.. Chronic renal failure after transplantation of nonrenal organ.  N Engl J Med. 2003;  349 931-940
  • 91 Vallejo G H, Romero C J, Vincente J C. Incidence and risk factors for cancer after liver transplantation.  Crit Rev Oncol Hematol. 2005;  56 87-99
  • 92 Herrero J I, Lorenzo M, Quiroga J et al.. De novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival.  Liver Transpl. 2005;  11 89-97
  • 93 Takaki A, Yagi T, Iwasaki Y et al.. Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation.  Transplantation. 2007;  83 231-233
  • 94 Fukumoto T, Berg T, Ku Y et al.. Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions.  Hepatology. 1996;  103 1351-1354
  • 95 Firpi R J, Zhu H, Morelli G et al.. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of sustained virological response after liver transplantation.  Liver Transpl. 2006;  12 51-57
  • 96 Watashi K, Hijikata M, Hosaka M et al.. Cyclosporine A suppresses replication of hepatitis C virus genome in cultured hepatocytes.  Hepatology. 2003;  38 1282-1288
  • 97 Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review.  Liver Transpl. 2006;  12 1813-1824
  • 98 Duclos Vallee J C, Sebagh M, Rifai K et al.. A 10 year follow-up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biological recurrence.  Gut. 2003;  52 893-897
  • 99 Liermann Garcia R F, Evangelista Garcia C, McMaster P, Neuberger J. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center.  Hepatology. 2001;  33 22-27
  • 100 Graziadei I W. Recurrence of primary sclerosing cholangitis after liver transplantation.  Liver Transpl. 2002;  8 575-581
  • 101 Goto T, Yamashita T, Ueda M et al.. Iatrogenic amyloid neuropathy in a Japanese patient after sequential liver transplantation.  Am J Transplant. 2006;  6 2512-2515
  • 102 Stangou A J, Heaton N, Hawkins P N. Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation.  N Engl J Med. 2005;  352 2356-2359
  • 103 Farese S, Trost N, Candinas D, Huynh-Do U. Early renal failure after domino hepatic transplantation using the liver from a compound heterozygous patient with primary hyperoxaluria.  Nephrol Dial Transplant. 2005;  20 2557-2560
  • 104 Franchello A, Paraluppi G, Romanogli R et al.. Severe course of primary hyperoxaluria and renal failure after domino hepatic transplantation.  Am J Transplant. 2005;  5 2324-2327
  • 105 Sousa M M, Ferrao J, Fernandes R et al.. Deposition and passage of transthyretin through the blood-nerve barrier in recipients of familial amyloid polyneuropathy livers.  Lab Invest. 2004;  84 865-873
  • 106 Takei Y, Gono T, Yazaki M et al.. Transthyretin-derived amyloid deposition on the gastric mucosa in domino recipients of familial amyloid polyneuropathy liver.  Liver Transpl. 2007;  13 215-218
  • 107 Chen Z, Yan L, Li B et al.. Successful adult-to-adult living donor liver transplantation combined with cadaveric split left lateral segment.  Liver Transpl. 2006;  12 1557-1559
  • 108 Heaton N, Srinivasan P, Prachalias A, Rela M. Overcoming the limitation of living donor and split liver transplantation: a proposal for adult recipients (the best of the East in the West).  Liver Transpl. 2008;  14 932-934

Professor Rene AdamAP-HP 

Hôpital Paul Brousse, Centre Hépato-Biliaire

12 Avenue Paul Vaillant Couturier, F-94804 Villejuif, France